LEXICON PHARMACEUTICALS, INC.
Small molecule drugs discovered and developed using gene science technology for cardiometabolic and chronic pain treatment
- Sector
- Biotech
- Headquarters
- The Woodlands, TX
- Latest Form D
- $55.7M, Feb 2026
- Total capital
- $446M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $446M
- 8 Form D · last Feb 2026
- 8 months since last filing
- Federal contracts
- $263K
- 25 awards · Veterans Affairs
- Rank in Biotech#279 of 4373
- Granted patents
- 15
- 25 pending · first 2015
- Rank in peer group#112 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$55.7M
- Private capital raisedForm D · SEC · 7th filing$72.2M
- Private capital raisedForm D · SEC · 6th filing$42.9M
- Federal contractVeterans Affairs · Lenvima 8MG Kit$11K
- Federal contractVeterans Affairs · Lenvima 8MG Kit$10K
- Federal contractVeterans Affairs · Lenvima 8 Mg$10K
- Federal contractVeterans Affairs · Lenvima 18 Mg$11K
- Private capital raisedForm D · SEC · 5th filing$10.5M
- Private capital raisedForm D · SEC · 4th filing$4.7M
- Private capital raisedForm D · SEC · 3rd filing$150M
- Private capital raisedForm D · SEC · 2nd filing$35M
- Private capital raisedForm D · SEC · 1st filing$75M
Show 19 earlier federal awards
- Federal contractVeterans Affairs · Xermelo 250 Mg$4K
- Federal contractVeterans Affairs · Lenvima 24 Mg$10K
- Federal contractVeterans Affairs · Xermelo$4K
- Federal contractVeterans Affairs · Xermelo$31K
- Federal contractVeterans Affairs · Xermelo 250MG$4K
- Federal contractVeterans Affairs · Xermelo$4K
- Federal contractVeterans Affairs · Telotristat Ethyl Xermelo 70183-0125-84$4K
- Federal contractVeterans Affairs · Xermelo 250MG Tabs$4K
- Federal contractVeterans Affairs · Xermelo$4K
- Federal contractVeterans Affairs · Xermelo 250 Mg$4K
- Federal contractVeterans Affairs · Telotristat Ethyl Xermelo 25 Mg Ndc 70183-0125-84 70183012584$4K
- Federal contractVeterans Affairs · Xermelo$4K
- Federal contractVeterans Affairs · Xermelo 250MG$4K
- Federal contractVeterans Affairs · Xermelo$4K
- Federal contractVeterans Affairs · Express Report: 16 Pharmacy Orders$118K
- Federal contractVeterans Affairs · Xermelo 250MG Tabs$4K
- Federal contractVeterans Affairs · Xermelo$4K
- Federal contractVeterans Affairs · Xermelo$4K
- Federal contractVeterans Affairs · Emergency Order$4K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
2 records have no date or no amount, so they aren’t placed on the timeline.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#112 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Suma T. GopinathanResearcherExecutive OfficerLinked by 1 patent
- Alan J. MainExecutive OfficerNamed in SEC Form D filings
- Alan S. NiesDirectorNamed in SEC Form D filings
- Alexander L. SantiniExecutive OfficerNamed in SEC Form D filings
- Brian T. CrumExecutive OfficerNamed in SEC Form D filings
- Brian P. ZambrowiczExecutive OfficerNamed in SEC Form D filings
Show all 31 people
- Christopher J. SobeckiDirectorNamed in SEC Form D filings
- Craig B. GranowitzExecutive OfficerNamed in SEC Form D filings
- Diane E. SullivanDirectorNamed in SEC Form D filings
- Frank P. PalantoniDirectorNamed in SEC Form D filings
- Ivan H. CheungDirectorNamed in SEC Form D filings
- James F. TessmerExecutive OfficerNamed in SEC Form D filings
- Jeffrey L. WadeExecutive OfficerNamed in SEC Form D filings
- John L. NorthcottExecutive OfficerNamed in SEC Form D filings
- Judith L. SwainDirectorNamed in SEC Form D filings
- Kenneth B. Kassler-TaubExecutive OfficerNamed in SEC Form D filings
- Kiernan A. SethExecutive OfficerNamed in SEC Form D filings
- Kristen L. AlexanderExecutive OfficerNamed in SEC Form D filings
- Lisa T. DeFrancescoExecutive OfficerNamed in SEC Form D filings
- Lonnel J. CoatsExecutive Officer, DirectorNamed in SEC Form D filings
- Mike T. ExtonExecutive Officer, DirectorNamed in SEC Form D filings
- Pablo L. LapuertaExecutive OfficerNamed in SEC Form D filings
- Philippe J. AmouyalDirectorNamed in SEC Form D filings
- Phillipe J. AmouyalDirectorNamed in SEC Form D filings
- Praveen L. TyleExecutive OfficerNamed in SEC Form D filings
- Rachel B. MartensExecutive OfficerNamed in SEC Form D filings
- Raymond F. DebbaneDirectorNamed in SEC Form D filings
- Robert J. LefkowitzDirectorNamed in SEC Form D filings
- Samuel L. BarkerDirectorNamed in SEC Form D filings
- Scott H. CoianteExecutive OfficerNamed in SEC Form D filings
- Wendy E. McDermottExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 15 granted of 40- GrantedSotagliflozin For Improving Left Atrial FunctionUSPTOUS 12,740,965
- GrantedCompounds And Methods For Treating SpasticityUSPTOUS 12,648,939
- GrantedContinuous Process For Preparing The Crystalline Form II Of SotagliflozinUSPTOUS 12,577,269
Show all 40 patent records
- Sotagliflozin For Improving Left Atrial FunctionSep 22, 2026 · US 12,740,965Granted
- Compounds And Methods For Treating SpasticityJun 9, 2026 · US 12,648,939Granted
- Continuous Process For Preparing The Crystalline Form II Of SotagliflozinMar 17, 2026 · US 12,577,269Granted
- Solid Forms Of (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE And Methods Of Their UseNov 13, 2025 · Application 19220294Pending
- Methods And Compounds Useful In The Synthesis Of An AAK1 InhibitorSep 11, 2025 · Application 19191629Pending
- Compounds And Methods Of Their UseSep 4, 2025 · Application 19052650Pending
- Compounds And Methods For Treating Chemotherapy-induced PainAug 21, 2025 · Application 19053009Pending
- Solid Forms Of (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE And Salts ThereofJul 1, 2025 · US 12,344,596Granted
- Methods And Compositions For The Treatment Of Hepatic EncephalopathyMay 29, 2025 · Application 18939816Pending
- Methods And Compounds Useful In The Synthesis Of An AAK1 InhibitorMay 27, 2025 · US 12,312,325Granted
- Methods Of Reducing The Risk Of Cardiovascular Events In Patients With Left Ventricular HypertrophyApr 10, 2025 · Application 18905496Pending
- Methods Of Treating Type 1 Diabetes And Kidney DiseaseApr 3, 2025 · Application 18897158Pending
- Use Of Sotagliflozin For The Treatment Of Patients With Type 1 Diabetes MellitusJul 11, 2024 · Application 18613381Pending
- Sotagliflozin For Improving Left Atrial FunctionMar 28, 2024 · Application 18270598Pending
- Compounds And Methods For Treating Viral InfectionsAug 22, 2023 · US 11,730,723Granted
- Compositions Comprising And Methods Of Using Inhibitors Of Sodium-glucose Cotransporters 1 And 2Jul 13, 2023 · Application 18095058Pending
- PYRAZOLO[1,5]PYRIMIDINE-BASED Compounds And Methods Of Their Use To Treat Viral InfectionsJun 6, 2023 · US 11,666,575Granted
- Compounds And Methods For Treating Or Preventing Cardiovascular Diseases And ConditionsNov 24, 2022 · Application 17574977Pending
- Use Of Sotagliflozin For The Treatment Of Patients With Type 2 Diabetes Mellitus And Moderate Renal ImpairmentAug 25, 2022 · Application 17629166Pending
- Process For Preparing The Crystalline Form II Of SotagliflozinJul 28, 2022 · Application 17631209Pending
- Use Of Sotagliflozin For The Treatment Of Patients With Type 1 Diabetes MellitusMar 24, 2022 · Application 17539548Pending
- Antibodies That Bind Notum PectinacetylesteraseJul 13, 2021 · US 11,059,907Granted
- Crystalline Solid Forms Of N-(1-((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-METHYL-1-OXOPROPAN-2-YL)-4-(4-(2-METHYL-5-((2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL)PHENYL)BUTANAMIDE And Methods Of Their SynthesisApr 6, 2021 · US 10,968,192Granted
- Use Of Sotagliflozin For The Treatment Of Patients With Type 1 Diabetes MellitusFeb 11, 2021 · Application 16804255Pending
- Compositions Comprising And Methods Of Using Inhibitors Of Sodium-glucose Cotransporters 1 And 2Feb 11, 2021 · Application 16792803Pending
- Sodium Glucose Co-transporter Inhibitors And Methods Of Their UseApr 4, 2019 · Application 15937496Pending
- Solid Dosage Forms Of (s)-ethyl 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATEJan 3, 2019 · Application 15613458Pending
- Inhibitors Of Sodium Glucose Transporter 1 For ConstipationOct 23, 2018 · US 10,106,569Granted
- PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USEJan 9, 2018 · US 9,862,724Granted
- Inhibitors Of Sodium Glucose Cotransporter 1Jun 27, 2017 · US 9,688,710Granted
- Inhibitors Of Adapter Associated Kinase 1, Compositions Comprising Them, And Methods Of Their UseJun 20, 2017 · US 9,682,982Granted
- Sodium Glucose Co-transporter Inhibitors And Methods Of Their UseMar 30, 2017 · Application 15155780Pending
- IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USEMar 2, 2017 · Application 15138460Pending
- PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USEAug 2, 2016 · US 9,403,832Granted
- Antibodies That Bind Notum PectinacetylesteraseJun 2, 2016 · Application 14952264Pending
- IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USEJan 28, 2016 · Application 14631097Pending
- Methods Of Lowering Blood PressureJan 28, 2016 · Application 14875903Pending
- Inhibitors Of Sodium Glucose Cotransporter 1Dec 1, 2015 · US 9,200,025Granted
- IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USEJul 2, 2015 · Application 14478479Pending
- PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USEJun 25, 2015 · Application 14478089Pending
Related companies, and why
- Organovo, Inc.Similar federal contract value in Biotech · $284K in contracts
- SYMBERIX, INC.Similar federal contract value in Biotech · $269K in contracts
- ZymergenSimilar federal contract value in Biotech · $267K in contracts
- AllCells, LLCSimilar federal contract value in Biotech · $261K in contracts
- Optys Tech CorporationSimilar federal contract value in Biotech · $252K in contracts
- PROTEIN FOUNDRY, LLCSimilar federal contract value in Biotech · $250K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .